299898-33-2
Chemical Structure
Acetyl Gastric Inhibitory Peptide (human)
Synonym(s): Human N-acetyl GIP
- CAS No.: 299898-33-2
- Formula:C228H340N60O67S
- Molecular Weight:5025.60
SMILES: O=C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](C)C(N[C@@H](CCC(O)=O)C(NCC(N[C@@H]([C@H](O)C)C(N[C@@H](CC2=CC=CC=C2)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CO)C(N[C@@H](CC(O)=O)C(N[C@@H](CC3=CC=C(C=C3)O)C(N[C@@H](CO)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](C)C(N[C@@H](CCSC)C(N[C@@H](CC(O)=O)C(N[C@@H](CCCCN)C(N[C@@H]([C@@H](C)CC)C(N[C@@H](CC4=CNC=N4)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC5=CC=CC=C5)C(N[C@@H](C(C)C)C(N[C@@H](CC(N)=O)C(N[C@@H](CC6=CNC7=CC=CC=C67)C(N[C@@H](CC(C)C)C(N[C@@H](CC(C)C)C(N[C@@H](C)C(N[C@@H](CCC(N)=O)C(N[C@@H](CCCCN)C(NCC(N[C@@H](CCCCN)C(N[C@@H](CCCCN)C(N[C@@H](CC(N)=O)C(N[C@@H](CC(O)=O)C(N[C@@H](CC8=CNC9=CC=CC=C89)C(N[C@@H](CCCCN)C(N[C@@H](CC%10=CNC=N%10)C(N[C@@H](CC(N)=O)C(N[C@@H]([C@@H](C)CC)C(N[C@@H]([C@H](O)C)C(N[C@@H](CCC(N)=O)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)C
Biological Activity: Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acetyl Gastric Inhibitory Peptide (human) | Acetyl Gastric Inhibitory Peptide (human) is a fatty acid derivatized analog of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties. Acetyl Gastric Inhibitory Peptide (human) can be used for research of diabetes, insulin resistance and obesity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. O'Harte FP, et al. Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP. Diabetologia. 2002 Sep;45(9):1281-91. [Content Brief]
- [2]. Gault Victor A, et al. GIP peptide analogues for treatment of diabetes, insulin resistance and obesity: World Intellectual Property Organization, WO2005082928[P]. 2005-12-01.
- [3]. O'Harte, et al. Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function: World Intellectual Property Organization, WO2007028632[P].2007-03-15.
